09:53 AM EDT, 07/23/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Tuesday it has received authorization from the Israeli Ministry of Health to start a phase I clinical trial to assess the safety and tolerability of Allocetra after injection into an affected joint in psoriatic arthritis patients.

The company said measuring the frequency and severity of adverse events and serious adverse events will be the primary safety endpoint of the trial, which currently plans to recruit six patients.

Enlivex said the secondary endpoints will include evaluations of change from baseline in pain and other parameters of disease activity for up to a year after administration of Allocetra.

Shares of Enlivex were down 0.7% in recent trading.

Price: 1.38, Change: -0.01, Percent Change: -0.72